Effect of preoperative immunonutrition on postoperative short-term clinical outcomes in patients with gastric cancer cachexia: a prospective randomized controlled trial.
Cancer cachexia
Enteral nutrition
Gastric cancer
Immunonutrition
Preoperative intervention
Journal
World journal of surgical oncology
ISSN: 1477-7819
Titre abrégé: World J Surg Oncol
Pays: England
ID NLM: 101170544
Informations de publication
Date de publication:
17 Apr 2024
17 Apr 2024
Historique:
received:
18
11
2023
accepted:
24
02
2024
medline:
19
4
2024
pubmed:
18
4
2024
entrez:
17
4
2024
Statut:
epublish
Résumé
Although current guidelines(ESPEN guideline: Clinical nutrition in surgery and other guidelines) recommend preoperative immunonutrition for cachectic gastric cancer patients, the strength of the recommendation is weak, and the level of evidence is low. The benefits of preoperative immunonutrition still remain controversial. 112 patients with gastric cancer cachexia were enrolled in the study and randomly assigned in a 1:1 ratio to receive either preoperative enteral immunonutrition support (IN, n = 56) or standard enteral nutrition support (SEN, n = 56). The primary endpoint was the incidence of infectious complications, and the secondary endpoints included the nutritional indicators, inflammatory markers, immune parameters, postoperative recovery and complications and gastrointestinal intolerance reactions. The incidence of postoperative infectious complications(P = 0.040) and overall complications (P = 0.049)was significantly lower in the IN group compared to the SEN group. In terms of laboratory inflammatory indexes, patients in the IN group demonstrated significantly lower levels of white blood cells (WBC), C-reactive protein (CRP), and interleukin-6 (IL-6), as well as higher levels of lymphocytes (LYMPH) and immunoglobulin A (IgA), compared to patients in the SEN group, with statistically significant differences. In terms of clinical outcomes, the IN group had a shorter duration of antibiotic use (P = 0.048), shorter hospital stay (P = 0.018), and lower total hospital costs (P = 0.034) compared to the SEN group. The IN group also experienced significantly less weight loss after surgery (P = 0.043). Preoperative administration of immunonutrition formula has a positive impact on the incidence of infectious complications in patients with gastric cancer cachexia after surgery. It improves patients' inflammatory and immune status, shortens hospital stays, and reduces healthcare costs. Preoperative use of immunonutrition may contribute to the improvement of prognosis in this high-risk population.
Sections du résumé
BACKGROUND
BACKGROUND
Although current guidelines(ESPEN guideline: Clinical nutrition in surgery and other guidelines) recommend preoperative immunonutrition for cachectic gastric cancer patients, the strength of the recommendation is weak, and the level of evidence is low. The benefits of preoperative immunonutrition still remain controversial.
PATIENTS AND METHODS
METHODS
112 patients with gastric cancer cachexia were enrolled in the study and randomly assigned in a 1:1 ratio to receive either preoperative enteral immunonutrition support (IN, n = 56) or standard enteral nutrition support (SEN, n = 56). The primary endpoint was the incidence of infectious complications, and the secondary endpoints included the nutritional indicators, inflammatory markers, immune parameters, postoperative recovery and complications and gastrointestinal intolerance reactions.
RESULTS
RESULTS
The incidence of postoperative infectious complications(P = 0.040) and overall complications (P = 0.049)was significantly lower in the IN group compared to the SEN group. In terms of laboratory inflammatory indexes, patients in the IN group demonstrated significantly lower levels of white blood cells (WBC), C-reactive protein (CRP), and interleukin-6 (IL-6), as well as higher levels of lymphocytes (LYMPH) and immunoglobulin A (IgA), compared to patients in the SEN group, with statistically significant differences. In terms of clinical outcomes, the IN group had a shorter duration of antibiotic use (P = 0.048), shorter hospital stay (P = 0.018), and lower total hospital costs (P = 0.034) compared to the SEN group. The IN group also experienced significantly less weight loss after surgery (P = 0.043).
CONCLUSION
CONCLUSIONS
Preoperative administration of immunonutrition formula has a positive impact on the incidence of infectious complications in patients with gastric cancer cachexia after surgery. It improves patients' inflammatory and immune status, shortens hospital stays, and reduces healthcare costs. Preoperative use of immunonutrition may contribute to the improvement of prognosis in this high-risk population.
Identifiants
pubmed: 38632641
doi: 10.1186/s12957-024-03348-y
pii: 10.1186/s12957-024-03348-y
pmc: PMC11022452
doi:
Types de publication
Randomized Controlled Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
101Informations de copyright
© 2024. The Author(s).
Références
Shock. 2002 Sep;18(3):217-22
pubmed: 12353921
Annu Rev Immunol. 2019 Apr 26;37:457-495
pubmed: 30676822
World J Surg. 2019 Mar;43(3):659-695
pubmed: 30426190
Ann Oncol. 2018 May 1;29(5):1141-1153
pubmed: 29788170
Nutrition. 2021 Apr;84:111109
pubmed: 33453622
Cancer Cell. 2023 Mar 13;41(3):581-584
pubmed: 36868225
Clin Biochem. 2017 Dec;50(18):1281-1288
pubmed: 28739222
Lancet. 2020 Aug 29;396(10251):635-648
pubmed: 32861308
World J Surg. 2006 Jul;30(7):1284-9
pubmed: 16830214
Ann Surg. 2021 Apr 1;273(4):725-731
pubmed: 30946082
Metabolism. 1996 Oct;45(10):1208-13
pubmed: 8843174
Ann Palliat Med. 2019 Jan;8(1):3-12
pubmed: 30685982
Best Pract Res Clin Anaesthesiol. 2004 Sep;18(3):439-54
pubmed: 15212338
Curr Opin Support Palliat Care. 2018 Dec;12(4):410-419
pubmed: 30124527
Lancet Oncol. 2011 May;12(5):489-95
pubmed: 21296615
Br J Surg. 2011 Jan;98(1):37-48
pubmed: 20931620
Clin Nutr. 2021 Jul;40(7):4745-4761
pubmed: 34242915
Nutrition. 1990 Jan-Feb;6(1):24-44; discussion 59-62
pubmed: 2135755
Surgery. 2014 Jan;155(1):124-33
pubmed: 24589090
World J Gastroenterol. 2009 Jan 28;15(4):467-72
pubmed: 19152452
Immunity. 2021 Dec 14;54(12):2701-2711
pubmed: 34910940
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
BMJ Open. 2023 Oct 10;13(10):e071714
pubmed: 37816552
Clin Nutr. 2010 Apr;29(2):154-9
pubmed: 20060626
Biochim Biophys Acta Rev Cancer. 2020 Apr;1873(2):188359
pubmed: 32222610
Ann Surg. 2022 Jan 1;275(1):e15-e21
pubmed: 33856385
Br J Surg. 2017 Nov;104(12):1594-1608
pubmed: 28940219
Ann Hematol. 2021 Jan;100(1):239-259
pubmed: 32997191
Nat Rev Cancer. 2014 Nov;14(11):754-62
pubmed: 25291291
Gastroenterology. 2002 Jun;122(7):1763-70
pubmed: 12055582
Nat Rev Dis Primers. 2018 Jan 18;4:17105
pubmed: 29345251
Ann Surg. 2019 Aug;270(2):247-256
pubmed: 30817349
Clin Nutr. 2017 Feb;36(1):11-48
pubmed: 27637832
Nutrition. 1998 Nov-Dec;14(11-12):831-5
pubmed: 9834924
Clin Nutr. 2021 May;40(5):2898-2913
pubmed: 33946039
Clin Sci (Lond). 2019 Oct 30;133(20):2061-2067
pubmed: 31654065
N Engl J Med. 1993 Dec 30;329(27):2002-12
pubmed: 7504210
World J Surg. 2009 Sep;33(9):1815-21
pubmed: 19629583
J Clin Invest. 2020 Sep 1;130(9):4921-4934
pubmed: 32544087
Nat Rev Endocrinol. 2018 Dec;15(1):9-20
pubmed: 30464312
Surgery. 2002 Nov;132(5):805-14
pubmed: 12464864
Nutr Cancer. 2021;73(11-12):2469-2476
pubmed: 33026250
Nat Rev Clin Oncol. 2023 Apr;20(4):250-264
pubmed: 36806788
J Postgrad Med. 2018 Jul-Sep;64(3):155-163
pubmed: 29848836
Cancer Med. 2017 Dec;6(12):2757-2765
pubmed: 29076260